Specifically, if anti-PD1/L1 is an anti-CSC therapy, it will be more effective when we combine it with a complementary anti-CSC therapy, such as an anti-TKI, anti-HER2, or anti-Nectin4, or with a supplementary anti-CSC therapy, such as an anti-metabolic treatment that modulates the CSC metabolism, and/or with an anti-inflammatory treatment that modulates the CSC niche, and just as importantly when we combine it with anti-non-CSC therapy, such as those that target differentiated cancer cells, e.g., AR-dependent, PSA-expressing prostate cancer cells. This evidence concerns the gene ERBB2 and cancer.